Key result
Nonpulsatile blood flow provided by the Heartmate II continuous-flow left ventricular assist device maintains end-organ function in patients with refractory heart failure awaiting transplant.
Why the study?
Does continuous-flow LVAD therapy impact end-organ function in patients with refractory heart failure awaiting a heart transplant?
Does continuous-flow LVAD therapy impact end-organ function in patients with refractory heart failure awaiting a heart transplant?
This editorial highlights that continuous, nonpulsatile blood flow from modern LVADs adequately supports end-organ function, challenging the historical belief that pulsatile flow is essential.
T he heart's natural provision of pulsatile blood flow has been regarded as an essential requirement for normal organ function, especially critical organs such as the kidney, liver, and brain. However, in this issue of Circulation, Russell and colleagues 1 have demonstrated that this tenet of medicine is no longer accurate. Their study examined the long-term impact of nonpulsatile blood flow as provided by a new generation of so-called continuous-flow left ventricular assist devices (LVADs), in this case the Heartmate II LVAD (Thoratec Corp, Pleasanton, Calif), on end-organ function in patients with refractory heart failure awaiting a heart transplant. These pumps draw blood from the left ventricle via a drainage cannula placed in the LV apex on a continuous basis and propel the blood by a rotary pump back into the circulation in a nonphasic flow pattern 2 through a return cannula connected to the aorta. The major findings of the Heartmate II clinical trial, including both the primary cohort 2 and a larger number of patients enrolled in the continuousaccess protocol, 3 have previously been reported.
No takes yet. Share an insight, caveat, or question.
Leslie W. Miller (2009) conducted an editorial in Refractory heart failure. Heartmate II LVAD (continuous-flow left ventricular assist device) was evaluated on End-organ function. Nonpulsatile blood flow provided by the Heartmate II continuous-flow left ventricular assist device maintains end-organ function in patients with refractory heart failure awaiting transplant.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: